Teva Pharma Unveils Long-Term Growth Strategy, Targets $6B-$7B In Innovative Medicines Revenue By 2030
Benzinga Newsdesk 1 hour ago
News
The Company has more than doubled revenue from innovative medicines since launching Pivot to Growth in 2023, demonstrating sustained execution and the growing strength of its high-velocity biopharma modelA live webcast
The Company has more than doubled revenue from innovative medicines since launching Pivot to Growth in 2023, demonstrating sustained execution and the growing strength of its high-velocity biopharma model
A live webcast of the event and presentation materials will be available on Teva’s Investor Relations website at Events and Presentations, with the webcast beginning at 8:30 a.m. EST today and concluding at 12:30 p.m. EST.
A dedicated media Q&A with Teva leadership will follow the webcast. The session is intended for members of the media, who can register to participate here.
TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today will host its first-ever R&D Day, outlining the next phase of the company’s growth and its ambition to generate $6–7 billion in innovative medicines revenue by 2030. President and CEO Richard Francis, together with members of Teva’s executive leadership and R&D teams, will highlight Teva’s advancing pipeline, differentiated R&D model and the potential to launch one innovative medicine per year over the next five years.